CompletedInterventionalPhase 4Updated Nov 19, 2008
Cosopt Versus Xalatan | NCT00273429 | Trialant
CompletedInterventionalPhase 4Updated Jan 9, 2007
Cosopt Versus Xalatan
ClinicalTrials.gov ID
NCT00273429
Lead Sponsor
Pharmaceutical Research NetworkOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Last Update Posted
Jan 9, 2007Estimated
Start Date
Apr 2005
Completion Date
Dec 2005
Brief Summary
To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
Open-Angle Glaucoma
Ocular Hypertension
timolol maleate 0.5%
dorzolamide/timolol maleate fixed combination
latanoprost 0.005%
placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
ETDRS visual acuity must be 1.0 or better in both eyes
Exclusion Criteria:
any contraindications to study medications
any anticipated change in systemic hypertensive therapy during the trial